oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Lennernäs, Bo
Publications (5 of 5) Show all publications
Lundin, E., Bergqvist, M., Ahlgren, J., Reizenstein, J. & Lennernäs, B. (2019). Validation of a Clinical Cancer Register at the Head and Neck Oncology Center in Orebro. Anticancer Research, 39(1), 285-289
Open this publication in new window or tab >>Validation of a Clinical Cancer Register at the Head and Neck Oncology Center in Orebro
Show others...
2019 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 39, no 1, p. 285-289Article in journal (Refereed) Published
Abstract [en]

Background: This was a validation study of a regional register of oral cancer in Örebro, Sweden. The purpose was to assess the rate of errors in baseline, and treatment, and the completeness and accuracy of data on recurrences.

Materials and Methods: A total of 653 cases with squamous cell cancer in the oral cavity were identified from the register. A randomized sample of 73 (11%) was selected, and a set of relevant data was compared to medical records.

Results: Data on patient and tumour characteristics showed high accuracy, with 98% correct data and more than 99% of treatment data were correct. Follow-up data had a higher rate of errors, with 23% of recurrences not recorded, 13.6% misclassified, and 9.1% of cases showing errors in timing of the recurrence.

Conclusion: data concerning patients, tumour status, and treatment in the Regional Head and Neck Register in Örebro are highly accurate. However, the follow-up data contain a higher rate of errors, that must be taken into consideration when evaluating outcome after treatment.

Place, publisher, year, edition, pages
International Institute of Anticancer Research, 2019
Keywords
Oral cancer, registry, register, validation
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-71348 (URN)10.21873/anticanres.13109 (DOI)000454413400036 ()30591470 (PubMedID)2-s2.0-85059224287 (Scopus ID)
Note

Funding Agency:

Forskningskommitten in Region Örebro län

Available from: 2019-01-11 Created: 2019-01-11 Last updated: 2019-01-11Bibliographically approved
Majumder, K., Brandberg, Y., Johansson, H., Castellanos, E., Ullén, A., Lennernäs, B. & Nilsson, S. (2018). Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study. Molecular and clinical oncology, 8(1), 141-146
Open this publication in new window or tab >>Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study
Show others...
2018 (English)In: Molecular and clinical oncology, ISSN 2049-9450, E-ISSN 2049-9469, Vol. 8, no 1, p. 141-146Article in journal (Refereed) Published
Abstract [en]

To avoid pubic arch interference, prostate cancer patients are treated with neoadjuvant androgen deprivation therapy (ADT) to achieve prostate volume (PV) reduction prior to radiation treatment. The aim of the present randomised study was to compare the effects on PV of two regimens of ADT, an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. Consecutive patients with non-metastatic prostate cancer were included in a randomised neoadjuvant study, comparing an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. PV was assessed prior to the start of endocrine neoadjuvant treatment and prior to the start of radiation therapy (RT). PV assessment was performed by transrectal ultrasound. A total of 110 patients were included. Final sample constituted 88 (80%) patients due to lack of PV information. Castration plus an androgen receptor inhibitor was more effective in PV reduction compared with an androgen receptor inhibitor alone (P<0.001). Planning target volume decreased in the combination arm. There was no significant difference in clinical or demographic or length of neoadjuvant hormonal treatment between the groups. Overall, a significantly larger PV reduction was achieved by castration plus androgen receptor inhibitor, as compared with androgen receptor inhibitor monotherapy. The PV reduction, however, appeared not to translate into better health associated quality of life during the subsequently given curative intended combined EBRT and HDR-brachytherapy. Potential differences between these two treatments regarding anti-tumor effects on micro metastatic disease and radiation potentiating effect remains to be addressed in future prospective trials.

Place, publisher, year, edition, pages
Spandidos Publications, 2018
Keywords
prostate cancer, neo-adjuvant, hormonal therapy, radiotherapy, prostate volume
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-72198 (URN)10.3892/mco.2017.1487 (DOI)000456297300026 ()29387407 (PubMedID)
Available from: 2019-02-07 Created: 2019-02-07 Last updated: 2019-02-07Bibliographically approved
Tammela, T. L., Häggman, M., Ladjevardi, S., Taari, K., Isotalo, T., Lennernäs, H., . . . Ahlström, H. (2017). An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. Journal of Urology, 198(6), 1333-1339
Open this publication in new window or tab >>An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer
Show others...
2017 (English)In: Journal of Urology, ISSN 0022-5347, E-ISSN 1527-3792, Vol. 198, no 6, p. 1333-1339Article in journal (Refereed) Published
Abstract [en]

Purpose: We investigated the tolerability, safety and antitumor effects of a novel intraprostatic depot formulation of antiandrogen 2-hydroxyflutamide (in Nano-Zolid (R)) in men with localized prostate cancer.

Materials and Methods: Two clinical trials, LPC-002 and LPC-003, were performed in a total of 47 men. The formulation was injected transrectally into the prostate under ultrasound guidance. In LPC-002 the effects on prostate specific antigen and prostate volume were measured for 6 months in 24 patients. In LPC-003 antitumor effects were evaluated by histopathology and magnetic resonance imaging including spectroscopy during 6 or 8 weeks in 23 patients. In each study testosterone and 2-hydroxyflutamide in plasma were measured as well as quality of life parameters.

Results: In LPC-002 (mean dose 690 mg) a reduction was observed in prostate specific antigen and prostate volume. Average nadir prostate specific antigen and prostate volume were 24.9% and 14.0% below baseline, respectively. When increasing the dose in LPC-003 to 920 and 1,740 mg, average prostate specific antigen decreased 16% and 23% after 6 and 8 weeks, respectively. Magnetic resonance imaging and magnetic resonance spectroscopy showed morphological changes and a global reduction in metabolite concentrations following treatment, indicating an antitumor response. Injections did not result in hormone related side effects. Three serious adverse events were reported and all resolved with oral antibiotic treatment.

Conclusions: Intraprostatic injections of 2-hydroxyflutamide depot formulations showed antitumor effects, and proved to be safe and tolerable. However, for better anticancer effects higher doses and better dose distribution are suggested.

Place, publisher, year, edition, pages
Elsevier, 2017
Keywords
prostatic neoplasms, prostate-specific antigen, androgen antagonists, delayed-action preparations, calcium sulfate
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-63426 (URN)10.1016/j.juro.2017.07.072 (DOI)000417150900023 ()28736321 (PubMedID)
Available from: 2017-12-19 Created: 2017-12-19 Last updated: 2018-08-13Bibliographically approved
Wikström, J., Isacsson, U., Johansson, B. & Lennernäs, B. (2017). Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study. Anticancer Research, 37(9), 4993-4996
Open this publication in new window or tab >>Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study
2017 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 37, no 9, p. 4993-4996Article in journal (Refereed) Published
Abstract [en]

Background/Aim: Electromagnetic Positioning Systems (EMP) is a new position-ing technique in four-dimensional radiotherapy. Patients with implanted transponders may be referred for magnetic resonance imaging (MRI) making it important to establish the MR safety.

Materials and Methods: Oranges were prepared with transponders and imaged on a 3T MR scanner with different sequences. Computed tomography (CT) was performed as comparison. MR artifacts were assessed. An estimation of the maximum transponder de-flection force and heating was made.

Results: The mean measured displacement of transponders was 0.1 mm (range=0.03-0.3 mm). Artifacts were observed adjacent to transponders using all sequences. The deflection force on the transponder in the gantry was less than 38 mN. No heating was observed.

Conclusion: The absence of any substantial movement, the weak measured deflection force and absence of observed heating speaks for the safe use of MR imaging with transponder 3T. Local artefacts makes evaluation impossible adjacent to transponders.

Place, publisher, year, edition, pages
International Institute of Anticancer Research, 2017
Keywords
Prostate cancer, electromagnetic positioning, four dimensional radiotherapy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-61934 (URN)10.21873/anticanres.11911 (DOI)000412578200034 ()28870923 (PubMedID)2-s2.0-85029427695 (Scopus ID)
Available from: 2017-10-24 Created: 2017-10-24 Last updated: 2018-08-07Bibliographically approved
Johansson, A. K., Lennernäs, B. & Isacsson, U. (2017). Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer. Anticancer Research, 37(4), 1825-1830
Open this publication in new window or tab >>Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer
2017 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 37, no 4, p. 1825-1830Article in journal (Refereed) Published
Abstract [en]

AIM: To quantify the impact of decreased margins for two treatment techniques, three-dimensional conformal radiotherapy (3D-CRT) and volumetric-modulated arc therapy (VMAT), on local control in curative treatment of prostate cancer.

MATERIALS AND METHODS: The planning target volume (PTV) margins were decreased in steps of 1 mm from 10 to 1 mm. Treatment plans using 3D-CRT and VMAT technique were produced for all margin sizes and the dose to the neuro vascular bundles (NVB), that was not included in the PTV, was investigated.

RESULTS: Due to the more conformal dose delivery using VMAT, the dose to the NVB decreased more rapidly by VMAT compared to the 3D-CRT plans. The dose difference was significant for margins from 1-7 mm.

CONCLUSION: One should be very cautious before clinical routines are changed, bearing in mind whether the change means more conformal treatment technique, smaller margins or target segmentation in different imaging modalities.

Place, publisher, year, edition, pages
International Institute of Anticancer Research, 2017
Keywords
Prostate cancer; local relapse; radiotherapy; 3D-CRT; VMAT
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-57342 (URN)10.21873/anticanres.11517 (DOI)000402167700035 ()28373447 (PubMedID)2-s2.0-85017442306 (Scopus ID)
Note

Funding Agency:

"Stiftelsen Onkologiska klinikens i Uppsala forskningsfond" (local foundation)

Available from: 2017-05-26 Created: 2017-05-26 Last updated: 2018-07-31Bibliographically approved
Organisations

Search in DiVA

Show all publications